Document is current

Article History

Received: 3 March 2024

Revised: 3 July 2024

Accepted: 9 July 2024

First Online: 19 August 2024

Declarations

:

: YS reports grants from Chugai Pharmaceutical, Kyowa-Kirin Co. Ltd., and Takeda Pharmaceuticals; contracts for clinical trials from Chugai Pharmaceutical and Takeda Pharmaceuticals; consulting fees from Takeda Pharmaceuticals; and payment/honoraria from Asahi Kasei, Chugai Pharmaceutical, CSL Behring, Novo Nordisk, Sanofi, and Takeda Pharmaceuticals. YO reports consulting fees and payment/honoraria from Chugai Pharmaceutical. TKikuchi reports no conflicts of interest. ES is an editor of the International Journal of Hematology, and reports consulting fees from Bristol Myers Squibb Japan, Otsuka Pharmaceutical, Servier, and Ohara Pharmaceutical Co. Ltd.; and payment/honoraria from Janssen Pharmaceuticals, Novartis, Pfizer, Sanofi, and Takeda Pharmaceuticals. YMizuta, TKitagawa, KT, and YMiyaguchi are all employees of Takeda Pharmaceuticals. KN reports grants and payment/honoraria from Bayer, Chugai Pharmaceutical, CSL Ltd., Fujimoto Pharmaceutical Corp., KM Biologics, Novo Nordisk, Sanofi, Sekisui, Sysmex, and Takeda Pharmaceuticals. TM reports grants from Chugai Pharmaceuticals and Novo Nordisk; consulting fees from Bayer, Chugai Pharmaceuticals, Novo Nordisk, Pfizer, and Takeda Pharmaceuticals; and payment/honoraria from Bayer, Chugai Pharmaceuticals, CSL, JB Pharma, KM Biologics, Novo Nordisk, Sanofi, Sysmex, and Takeda Pharmaceuticals.

: The study protocol, informed consent form, and all amendments were reviewed and approved by the local institutional review board at each investigator site before study initiation. The study was conducted in accordance with the Declaration of Helsinki and the principles and guidelines described in the study protocol.

: All patients provided written informed consent (either in person or via a legal decision maker) prior to entering the study and were free to withdraw from the study at any time.